NasdaqGS - Nasdaq Real Time Price USD

Enanta Pharmaceuticals, Inc. (ENTA)

12.61 -0.31 (-2.40%)
As of 9:30 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
73,622.00
79,204.00
86,160.00
97,074.00
122,473.00
Operating Expense
215,702.00
216,411.00
210,004.00
206,647.00
164,112.00
Operating Income
-142,080.00
-137,207.00
-123,844.00
-109,573.00
-41,639.00
Net Non Operating Interest Income Expense
6,076.00
6,212.00
1,573.00
2,021.00
6,471.00
Other Income Expense
--
--
83.00
-27.00
149.00
Pretax Income
-136,004.00
-130,995.00
-122,188.00
-107,579.00
-35,019.00
Tax Provision
2,233.00
2,821.00
-433.00
-28,583.00
1,149.00
Net Income Common Stockholders
-138,237.00
-133,816.00
-121,755.00
-78,996.00
-36,168.00
Diluted NI Available to Com Stockholders
-138,237.00
-133,816.00
-121,755.00
-78,996.00
-36,168.00
Basic EPS
-6.57
-6.38
-5.91
-3.92
-1.81
Diluted EPS
-6.57
-6.38
-5.91
-3.92
-1.81
Basic Average Shares
21,037.00
20,969.00
20,603.00
20,171.00
19,940.00
Diluted Average Shares
21,037.00
20,969.00
20,603.00
20,171.00
19,940.00
Total Operating Income as Reported
-142,080.00
-137,207.00
-123,844.00
-109,573.00
-41,639.00
Total Expenses
215,702.00
216,411.00
210,004.00
206,647.00
164,112.00
Net Income from Continuing & Discontinued Operation
-138,237.00
-133,816.00
-121,755.00
-78,996.00
-36,168.00
Normalized Income
-138,237.00
-133,816.00
-121,755.00
-78,996.00
-36,276.77
Interest Income
14,665.00
11,360.00
1,573.00
2,021.00
6,471.00
Interest Expense
8,589.00
5,148.00
--
--
--
Net Interest Income
6,076.00
6,212.00
1,573.00
2,021.00
6,471.00
EBIT
-127,415.00
-125,847.00
-122,188.00
-107,579.00
-41,639.00
EBITDA
-124,913.00
-123,476.00
-119,215.00
-104,245.00
-37,995.00
Reconciled Depreciation
2,502.00
2,371.00
2,973.00
3,334.00
3,644.00
Net Income from Continuing Operation Net Minority Interest
-138,237.00
-133,816.00
-121,755.00
-78,996.00
-36,168.00
Total Unusual Items Excluding Goodwill
--
--
83.00
-27.00
149.00
Total Unusual Items
--
--
83.00
-27.00
149.00
Normalized EBITDA
-124,913.00
-123,476.00
-119,215.00
-104,245.00
-38,144.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
--
--
40.23
9/30/2020 - 3/21/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ITOS iTeos Therapeutics, Inc.
10.40
-1.61%
 
MGNX MacroGenics, Inc.
15.25
-2.87%
 
AGIO Agios Pharmaceuticals, Inc.
31.43
-0.77%
 
XENE Xenon Pharmaceuticals Inc.
39.33
-0.43%
 
PEPG PepGen Inc.
11.61
-1.86%
 
PTCT PTC Therapeutics, Inc.
24.59
-2.48%
 
IKNA Ikena Oncology, Inc.
1.2800
-0.78%
 
PTGX Protagonist Therapeutics, Inc.
25.10
-2.33%
 
KALV KalVista Pharmaceuticals, Inc.
10.15
-1.95%
 
MGTX MeiraGTx Holdings plc
4.8100
-1.03%